VCT220 / CX11
VCT220 · CX11 · oral small-molecule GLP-1 receptor agonist · CORXEL / Vincentage Pharma
The same oral small-molecule GLP-1 medicine is called VCT220 in China and CX11 outside Greater China; obesity studies are at different stages by region.
Selected study results
VCT220 · China Phase 3 · 120 mgMean body-weight reductionBody weight decreased 12.2% · 52 weeks · Phase 3
Mean body-weight reduction · 52 weeks
Study focus: Weight management
A separate 160 mg group had 12.4% mean weight reduction; both China Phase 3 dose groups are reported below.
Adults with obesity or overweight and a weight-related comorbidity in China · 120 mg once daily vs placebo · Trial N=840 · Sponsor topline. Results & methods ↗
- Same China Phase 3 study · 160 mg groupThe separate 160 mg group had 12.4% mean body-weight reduction versus 1.3% with placebo at 52 weeks. It is a dose arm within the same trial, not a separate study.
Sponsor topline from a China trial; results are not head-to-head with the separate U.S. Phase 2 study.
CX11 · U.S. Phase 2Maximum reported mean body-weight reduction across four regimensBody weight decreased 11.5% · 36-week follow-up; primary endpoint at week 26 · Phase 2
Maximum reported mean body-weight reduction across four regimens · 36-week follow-up; primary endpoint at week 26
Study focus: Weight management
Sponsor-reported full results from a randomized, double-blind, placebo-controlled U.S. trial.
Adults with obesity or overweight in the United States · 120 mg, 160 mg, or 200 mg with fast or slow titration, once daily · Trial N=246 · Per-protocol set; least-squares means; hypothetical handling of intercurrent events. Results & methods ↗
| Timepoint | CX11 mean weight reduction | Placebo |
|---|---|---|
| Week 26 · primary endpoint | 8.0–9.0% | 2.8% |
| Week 36 · follow-up | 9.3–11.5% | 3.1% |
- U.S. Phase 2 · safetyDiscontinuation for gastrointestinal treatment-emergent adverse events was 5.0% across the combined CX11 groups versus 2.2% with placebo. Gastrointestinal events occurred mainly during dose escalation and were mild to moderate.
The 11.5% chart value is the maximum across four regimens, not a pooled mean. The release reports ranges without mapping each mean weight change to a dose. This U.S. Phase 2 trial is separate from China VCT220; global Phase 3 remains planned.
Each graphic shows results within one study. Alternate analyses and follow-up from that study are labeled together. Study averages are not individual predictions or cross-trial comparisons.
Mechanism at a glance
Obesity stage by formulation
Latest: China Phase 3 VCT220 topline and U.S. Phase 2 CX11 topline were reported. CORXEL says that following an End-of-Phase-2 meeting it aligned with the FDA on key elements of CX11’s Phase 3 design and regulatory path; global Phase 3 is planned and in preparation.
Next: Global Phase 3 initiation and design; China NDA submission.
Clinical study records
Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.
Obesity and weight-management studies
Phase 3 studies1 record
VCT220 China obesity Phase 3
Weight managementNCT06939296; 840 participants; 52-week Phase 3 study in China.
Phase 2 studies1 record
CX11 U.S. obesity Phase 2
Weight management246 adults in a 36-week U.S. placebo-controlled study. Primary weight endpoint at week 26; week-36 follow-up and pooled safety are reported separately. Global Phase 3 is planned, not initiated.
